HC Wainwright Has Bullish Outlook for BTAI FY2024 Earnings

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – HC Wainwright increased their FY2024 earnings per share (EPS) estimates for BioXcel Therapeutics in a research report issued on Thursday, January 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($1.48) per share for the year, up from their previous forecast of ($2.03). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.60) EPS.

Other research analysts also recently issued research reports about the company. Canaccord Genuity Group reduced their price target on BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Bank of America reiterated an “underperform” rating and set a $0.25 target price (down previously from $7.00) on shares of BioXcel Therapeutics in a report on Tuesday, January 7th.

BioXcel Therapeutics Trading Down 5.6 %

BTAI opened at $0.31 on Monday. The company has a market cap of $15.27 million, a P/E ratio of -0.14 and a beta of -0.01. The business’s 50-day moving average price is $0.39 and its 200-day moving average price is $0.58. BioXcel Therapeutics has a 12 month low of $0.29 and a 12 month high of $4.17.

Institutional Trading of BioXcel Therapeutics

A hedge fund recently bought a new stake in BioXcel Therapeutics stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 30,295 shares of the company’s stock, valued at approximately $39,000. Point72 Asia Singapore Pte. Ltd. owned about 0.08% of BioXcel Therapeutics at the end of the most recent reporting period. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.